What Happened?
Shares of life sciences company Bio-Techne (NASDAQ: TECH) jumped 5.3% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations.
As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry.
The shares closed the day at $55.64, up 6.5% from previous close.
Is now the time to buy Bio-Techne? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Bio-Techne’s shares are quite volatile and have had 19 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 20 days ago when the stock dropped 4.8% on the news that the company presented a cautious outlook at the Baird Global Healthcare Conference, highlighting significant market challenges despite some areas of growth.
During the presentation, Bio-Techne reported 3% organic growth for the fourth quarter, driven by double-digit growth in its pharma segment and in China. However, this positive news was overshadowed by hurdles in other key areas. The company noted a decline in the U.S. academic market and pointed to unpredictability in the biotech sector, which is suffering from "dramatic funding declines."
Management stated it is navigating these uncertain market conditions with a cautious approach, which appears to have concerned investors about the company's near-term performance.
Bio-Techne is down 22.2% since the beginning of the year, and at $55.63 per share, it is trading 30.4% below its 52-week high of $79.93 from September 2024. Investors who bought $1,000 worth of Bio-Techne’s shares 5 years ago would now be looking at an investment worth $898.24.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
